| Name | Title | Contact Details |
|---|
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck`s proprietary Agonist Redirected Checkpoint, ARCĀ®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company`s lead wholly owned program, SL-172154 (SIRPĪ±-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLENā¢, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina.
BD Biosciences - Canada is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BIOSPECTRA, INC. is a Stroudsburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Treasure Coast Radiation Oncology, Pa is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.